The expediency of application of metabolic therapy for correcting changes of the myocardium on the background of diabetes mellitus

  • V. G. Lizogub Bohomolets National Medical University
  • T. V. Zavalskaya Bohomolets National Medical University
  • Y. O. Belikova Bohomolets National Medical University
Keywords: Coronary Heart Disease, Diabetes Mellitus, L-Arginine

Abstract

The published data about basic pathogenetic mechanisms of myocardial abnormalities due to diabetes, damage of cardiomyocytes and neurovegetative microcirculatory disorders.The expediency of application of metabolic therapy for correction these disorders, in particular, the amino acid L-arginine (Tivortin®) – substrate for nitrogen oxide synthesis.

Downloads

Download data is not yet available.

References

Dobordzhginadze L. M., Gracianskij Ya. Osobennosti diabeticheskoj dislipidemii i puti ee korrekcii: effekt statinov // Probl. endokrinologii. – 2001. – T. 47, № 5. – S. 35–40.
Efimov A. S., Mankovskij B. N., Kostyuk E. P. i dr. Aktualnye voprosy lecheniya saharnogo diabeta i ego oslozhnenij // Zhurn. AMN Ukrayini. – T. 6, № 3. – 2009. – S. 460–471.
Stepanov Yu. M., Kononov I. N., Zhurbina A. I., Filippova A. Yu. Arginin v medicinskoj praktike // Zhurn. AMN Ukrayini. – 2004. – T. 10, № 1. – S. 340–352.
American Diabetes Association and American Academy of Neurology.Report and recommendations of the San Antonio conferenct on diabetic neuropathy // Diabetes Care. – 1988. – Vol. 11, N 1. – P. 592–597.
Backer G. De, Ambrosioni E., Borch–Johnsen K. et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardio-vascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) // Eur. J. Cardiovasc. Prev. Rehabil. – 2012. – Vol. 10, Suppl. 1. – P. 1–8.
Baylis C. Nitric oxide deficiency in chronic kidney disease // Am. J. Physiol. Renal. Physiol. – 2008. – Vol. 294. – P. 1–9.
Bednarz B., Jaxa-Chamiec T., Maciejewski P. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial // Kardiol. Pol. – 2005. – Vol. 62, N 5. – P. 421–427.
Bode-Böger S.M., Muke J., Surdacki A. et al. Oral L-arginine improves endothelial function in healthy individuals older than 70 years // Vasc. Med. – 2003. – Vol. 8, N 2. – P. 77–81.
Boger R. H. The pharmacodynamics of L-arginine /R. H. Boger // J. Nutr. – 2007. – Vol. 137. – P. 1650–1655.
Despres J. P., Lamarche B., Mauriege P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease // N. Engl. J. Med. – 1996. – Vol. 334, N 15. – P. 952–957.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults // JAMA. – 2010. – Vol. 285, N 19. – P. 2486–2497.
Facchinetti F., Saade G. R., Neri I. et al. L-arginine supplementation in patients with gestational hypertension: a pilot study // Hypertens Pregnancy. – 2007. – Vol. 26, N 1. – P. 1327–1333.
Feskens E. J., Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study // J. Clin. Epidemiol. – 2012. – Vol. 45, N 11. – P. 1327–1333.
Gkaliagkousi E., Ritter J., Ferro A. Platelet-derived nitric oxide signaling and regulation // Circ. Res. – 2007. – Vol. 101, N 7. – P. 654–662.
Gornik H. L., Creager M. A. Arginine and endothelial and vascular health // J. Nutr. – 2004 – Vol. 134. – P. 2880S–2887S.
Haffner S. M. Lehto S., Ronnema Т. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in noniabetic subjects with and without prior myocardial infarction // N. Engl. J. Med. – 2012. – Vol. 339. – P. 229–234.
Herlitz J., Karlson B. W., Lindqvist J., Sjolin M. Rate and mode of death during five years of follow–up among patients with acute chest pain with and without a history of diabetes mellitus // Diabet. Med. – 1998. – Vol. 15, N 4. – P. 308–314.
Hurst R. Т., Lee R. W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management // Ann. Intern. Med. – 2003. – Vol. 139. – P. 824–834.
Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta–analysis of 37 prospective cohort studies // BMJ. – 2006. – Vol. 332, N 7533. – P. 73–78.
Jabłecka A., Checiński P., Krauss H. et al. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients // Med. Sci. Monit. – 2004. – Vol. 10, N 1. – P. 29–32.
Kjaergaard S. C., Hansen H. H., Fog L. et al. Inhospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era // Scand. Cardiovasc. J. – 1999. – Vol. 33. – Р. 166–170.
Lehto S., Ronnemaa T., Pyorala K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes // Diabetologia. – 2000. – Vol. 43, N 2. – P. 148–155.
Lekakis J. P., Papathanassiou S., Papaioannou T. G. et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension // Int. J. Cardiol. – 2002. – Vol. 86, N 2–3. – P. 317–323.
Malmberg K., Yusuf S., Gerstein H. С. et al. Impact of diabetes on long–term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry // Cir-culat. – 2000. – Vol. 102, N 9. – P. 1014–1019.
Maxwell A. J., Anderson B., Zapien M. P., Cooke J. P. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity // Cardiovasc. Drugs Ther. – 2000. – Vol. 14, N 3. – P. 309–316.
Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction The FINMONICA Myocardial Infarction Register Study Group // Diabetes Care. – 1998. – Vol. 21, N 1. – Р. 69–75.
Moutaouakil F., El Otmani H., Fadel H. et al. L-arginine efficiency in MELAS syndrome. A case report // Rev. Neurol. – 2009. – Vol. 165, N 5. – P. 482–485.
Okamoto M., Etani H., Yagita Y. et al. Diminished reserve for cerebral vasomotor response to L-arginine in the elderly: evaluation by transcranial Doppler sonography // Gerontology. – 2001. – Vol. 47, N 3. – P. 131–135.
Timmis A. D. Diabetic heart disease: clinical considerations // Heart. – 2010. – Vol. 85, N 4. – P. 463–469.
Tsuruta M., Hashimoto R., Adachi H. et al. Hyperinsulinaemia as a predictor of hypertension: an 11-year follow-up study in Japan // J. Hypertension. – 1996. – Vol. 14. – P. 483–488.
Turner R. С., Millns H., Neil H. A. et al. Risk factors for coronary artery disease in non–insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) // BMJ. – 1998. – Vol. 316, N 7134. – P. 823–828.
Wannamethee S. G., Shaper A. G., Lennon L. Cardio vascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease // Heart. – 2009. – Vol. 90, N 12. – P. 1398–1403.

Abstract views: 90
PDF Downloads: 90
Published
2017-12-30
How to Cite
Lizogub, V. G., Zavalskaya, T. V., & Belikova, Y. O. (2017). The expediency of application of metabolic therapy for correcting changes of the myocardium on the background of diabetes mellitus. Likars’ka Sprava, (8), 35-42. https://doi.org/10.31640/LS-2017-8-04
Section
Surveys of literature